Shi Wei, Shi Yuan-kai, He Xiao-hui, Zhou Sheng-yu, Dong Mei, Zhang Chang-gong, Yang Jian-liang, Liu Peng, Qin Yan, Yang Sheng, Gui Lin
Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Zhonghua Yi Xue Za Zhi. 2010 Apr 13;90(14):978-81.
The efficacy of standard chemotherapy regimen on lymphoblastic lymphoma (LBL) is unsatisfied. This study was to evaluate the efficacy and safety of modified Hyper-CVAD regimen on Chinese patients with LBL.
Clinical records of 20 LBL patients who received modified Hyper-CVAD regimen in Cancer Hospital of Chinese Academy of Medical Sciences, from June 2004 to June 2008, were retrospectively analyzed in terms of response and toxicity.
By May. 2009, the median follow-up time was 17 (4-36) months. The 20 patients totally received 62 cycles regimen A and 29 cycles regimen B. 17 patients were assessable in efficacy, the total response rate (RR) was 88.2% with complete response (CR) rate of 41.2%. 15 patients received modified Hyper-CVAD regimen as first-line therapy (75.0%), and RR was 100% with CR rate of 50.0% (7/14). The RR of salvage therapy was 33% without CR achieved. The major toxicity was myelosuppression, the incidence of grades 3-4 neutropenia, thrombocytopenia and anemia was 95.0%, 75.0% and 40.0%, respectively. No treatment-related death was observed.
Modified Hyper-CVAD regimen was a promising regimen for the patients with LBL, and toxicity was within acceptable limits.
标准化疗方案对淋巴细胞淋巴瘤（LBL）的疗效不尽人意。本研究旨在评估改良Hyper-CVAD方案对中国LBL患者的疗效和安全性。
回顾性分析2004年6月至2008年6月在中国医学科学院肿瘤医院接受改良Hyper-CVAD方案治疗的20例LBL患者的临床记录，分析其缓解情况和毒性反应。
至2009年5月，中位随访时间为17（4 - 36）个月。20例患者共接受62个周期的A方案和29个周期的B方案治疗。17例患者可评估疗效，总缓解率（RR）为88.2%，完全缓解（CR）率为41.2%。15例患者接受改良Hyper-CVAD方案作为一线治疗（75.0%），RR为100%，CR率为50.0%（7/14）。挽救治疗的RR为33%，未达到CR。主要毒性为骨髓抑制，3 - 4级中性粒细胞减少、血小板减少和贫血的发生率分别为95.0%、75.0%和40.0%。未观察到与治疗相关的死亡。
改良Hyper-CVAD方案对LBL患者是一种有前景的方案，且毒性在可接受范围内。
